1.
Gu C, Cheng H, Yang H, Bian Y, Wang Y, Zhang Y, Pisano M, Hu G, Yang Y. MK2 is a therapeutic target for high-risk multiple myeloma. Haematologica 2021; 106(6):1774-1777; https://doi.org/10.3324/haematol.2017.182121.